{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:49:04Z","timestamp":1793789344588,"version":"4.6.1"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10620-024-08716-y","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T22:59:15Z","timestamp":1731538755000},"page":"4336-4346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic Abdominal Pain in Patients with Inflammatory Bowel Disease in Remission: A Continuing Challenge for Clinicians"],"prefix":"10.1007","volume":"69","author":[{"given":"Natasha","family":"Klemm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvee","family":"Moosavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"8716_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00384-020-03727-3","volume":"36","author":"MD Coates","year":"2021","unstructured":"Coates MD, Johri A, Gorrepati VS et al. Abdominal pain in quiescent inflammatory bowel disease. Int J Colorectal Dis 2021;36:93\u2013102.","journal-title":"Int J Colorectal Dis"},{"key":"8716_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/j.pain.0000000000001390","volume":"160","author":"M Nicholas","year":"2019","unstructured":"Nicholas M, Vlaeyen JWS, Rief W et al. The IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain 2019;160:28\u201337.","journal-title":"Pain"},{"key":"8716_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0135-7","volume":"6","author":"AM Drewes","year":"2020","unstructured":"Drewes AM, Olesen AE, Farmer AD et al. Gastrointestinal pain. Nat Rev Dis Primers 2020;6:1.","journal-title":"Nat Rev Dis Primers"},{"key":"8716_CR4","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.14309\/ajg.0000000000002267","volume":"118","author":"KA Dunleavy","year":"2023","unstructured":"Dunleavy KA, Cross RK, Raffals LE. Causes, diagnostic testing, and treatment of residual symptoms in patients with IBD with quiescent disease. Am J Gastroenterol 2023;118:1909\u20131914.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR5","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s10620-023-08095-w","volume":"68","author":"J Lim","year":"2023","unstructured":"Lim J, Rezaie A. Irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease: a practical approach to diagnosis and treatment of organic causes. Dig Dis Sci 2023;68:4081\u20134097. https:\/\/doi.org\/10.1007\/s10620-023-08095-w.","journal-title":"Dig Dis Sci"},{"key":"8716_CR6","first-page":"1","volume":"5","author":"MD Coates","year":"2023","unstructured":"Coates MD, Clarke K, Williams E et al. Abdominal pain in inflammatory bowel disease: an evidence-based, multidisciplinary review. Crohn\u2019s Colitis 360 2023;5:1\u201318.","journal-title":"Crohn\u2019s Colitis 360"},{"key":"8716_CR7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/apt.15133","volume":"49","author":"A Shah","year":"2018","unstructured":"Shah A, Morrison M, Burger D et al. Systematic review with meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease. Aliment Pharmacol Ther 2018;49:624\u2013635.","journal-title":"Aliment Pharmacol Ther"},{"key":"8716_CR8","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ajg.2012.260","volume":"107","author":"SJ Halpin","year":"2012","unstructured":"Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012;107:1474\u20131482.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S2468-1253(20)30300-9","volume":"5","author":"KM Fairbrass","year":"2020","unstructured":"Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:1053\u20131062.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"8716_CR10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S2468-1253(19)30089-5","volume":"4","author":"DJ Gracie","year":"2019","unstructured":"Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain\u2013gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol 2019;4:632\u2013642.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"8716_CR11","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1007\/s10620-023-08075-0","volume":"68","author":"MD Coates","year":"2023","unstructured":"Coates MD, Dalessio S, Walter V et al. Lifestyle factors associated with abdominal pain in quiescent inflammatory bowel disease. Dig Dis Sci 2023;68:4156\u20134165. https:\/\/doi.org\/10.1007\/s10620-023-08075-0.","journal-title":"Dig Dis Sci"},{"key":"8716_CR12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MIB.0000000000001017","volume":"23","author":"MII Abdalla","year":"2017","unstructured":"Abdalla MII, Sandler RS, Kappelman MD et al. Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partners. Inflamm Bowel Dis 2017;23:325\u2013331.","journal-title":"Inflamm Bowel Dis"},{"key":"8716_CR13","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.cgh.2023.01.017","volume":"21","author":"MHMA Bosman","year":"2023","unstructured":"Bosman MHMA, Weerts ZZRM, Snijkers JTW et al. The socioeconomic impact of irritable bowel syndrome: an analysis of direct and indirect health care costs. Clin Gastroenterol Hepatol 2023;21:2660\u20132669.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8716_CR14","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/jcag\/gwad009","volume":"6","author":"ME Kuenzig","year":"2023","unstructured":"Kuenzig ME, Im JHB, Coward S et al. The 2023 impact of inflammatory bowel disease in Canada: indirect (individual and societal) and direct out-of-pocket costs. J Can Assoc Gastroenterol 2023;6:S16\u2013S22.","journal-title":"J Can Assoc Gastroenterol"},{"key":"8716_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-14838-y","volume":"12","author":"K Bogale","year":"2022","unstructured":"Bogale K, Maheshwari P, Kang M et al. Symptoms associated with healthcare resource utilization in the setting of inflammatory bowel disease. Sci Rep 2022;12:1\u20138.","journal-title":"Sci Rep"},{"key":"8716_CR16","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1007\/s10620-021-07025-y","volume":"67","author":"A Al Khoury","year":"2022","unstructured":"Al Khoury A, Balram B, Bessissow T et al. Patient perspectives and expectations in inflammatory bowel disease: a systematic review. Dig Dis Sci 2022;67:1956\u20131974. https:\/\/doi.org\/10.1007\/s10620-021-07025-y.","journal-title":"Dig Dis Sci"},{"key":"8716_CR17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/PPA.S152872","volume":"12","author":"JC Gregor","year":"2018","unstructured":"Gregor JC, Williamson M, Dajnowiec D, Sattin B, Sabot E, Salh B. Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: results of a prospective cross-sectional willingness-to-pay study. Patient Prefer Adherence 2018;12:505\u2013513.","journal-title":"Patient Prefer Adherence"},{"key":"8716_CR18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/ecco-jcc\/jjac130","volume":"17","author":"E Louis","year":"2023","unstructured":"Louis E, Siegel CA, James B, Heidenreich S, Krucien N, Ghosh S. Patients with inflammatory bowel disease have heterogeneous treatment preferences that are largely determined by the avoidance of abdominal pain and side effects [P-POWER IBD Study]. J Crohn\u2019s Colitis 2023;17:231\u2013239.","journal-title":"J Crohn\u2019s Colitis"},{"key":"8716_CR19","first-page":"1","volume":"360","author":"SN Balbale","year":"2022","unstructured":"Balbale SN, Iroz CB, Sch\u00e4fer WLA, Johnson JK, Stulberg JJ. A missing piece of the puzzle: patient and provider perspectives on pain management needs and opioid prescribing in inflammatory bowel disease care. Crohn\u2019s Colitis 2022;360:1\u201315.","journal-title":"Crohn\u2019s Colitis"},{"key":"8716_CR20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11894-020-0757-7","volume":"22","author":"E Weaver","year":"2020","unstructured":"Weaver E, Szigethy E. Managing pain and psychosocial care in IBD: a primer for the practicing gastroenterologist. Curr Gastroenterol Rep 2020;22:20.","journal-title":"Curr Gastroenterol Rep"},{"key":"8716_CR21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cgh.2018.08.001","volume":"17","author":"JF Colombel","year":"2019","unstructured":"Colombel JF, Shin A, Gibson PR. AGA clinical practice update on functional gastrointestinal symptoms in patients with inflammatory bowel disease: expert review. Clin Gastroenterol Hepatol 2019;17:380-390.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8716_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1756283X15621230","volume":"9","author":"EMM Quigley","year":"2016","unstructured":"Quigley EMM. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Ther Adv Gastroenterol 2016;9:199\u2013212.","journal-title":"Ther Adv Gastroenterol"},{"key":"8716_CR23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","volume":"116","author":"BE Lacy","year":"2020","unstructured":"Lacy BE, Pimentel M, Brenner DM et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 2020;116:17\u201344.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gutjnl-2021-324598","volume":"70","author":"DH Vasant","year":"2021","unstructured":"Vasant DH, Paine PA, Black CJ et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 2021;70:1\u201327.","journal-title":"Gut"},{"key":"8716_CR25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.clnu.2017.05.019","volume":"37","author":"Y Le Zhan","year":"2018","unstructured":"Le Zhan Y, An Zhan Y, Xue Dai S. Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. Clin Nutr 2018;37:123\u2013129.","journal-title":"Clin Nutr"},{"key":"8716_CR26","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.3748\/wjg.v23.i18.3356","volume":"23","author":"N Pedersen","year":"2017","unstructured":"Pedersen N, Ankersen DV, Felding M et al. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World J Gastroenterol 2017;23:3356\u20133366.","journal-title":"World J Gastroenterol"},{"key":"8716_CR27","first-page":"1","volume":"12","author":"MG Grammatikopoulou","year":"2020","unstructured":"Grammatikopoulou MG, Goulis DG, Gkiouras K et al. Low FODMAP diet for functional gastrointestinal symptoms in quiescent inflammatory bowel disease: a systematic review of randomized controlled trials. Nutrients 2020;12:1\u201322.","journal-title":"Nutrients"},{"key":"8716_CR28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/nu14061296","volume":"14","author":"D Melgaard","year":"2022","unstructured":"Melgaard D, S\u00f8rensen J, Riis J et al. Efficacy of FODMAP elimination and subsequent blinded placebo-controlled provocations in a randomised controlled study in patients with ulcerative colitis in remission and symptoms of irritable bowel syndrome: a feasibility study. Nutrients 2022;14:4\u20137.","journal-title":"Nutrients"},{"key":"8716_CR29","first-page":"4","volume":"101","author":"B Gu","year":"2022","unstructured":"Gu B, Yu Z, Shi C, Yan C, Chen B, Zhou J. Effects of low-FODMAP diet on irritable bowel symptoms in patients with quiescent inflammatory bowel disease. Medicine (United States) 2022;101:4\u20137.","journal-title":"Medicine (United States)"},{"key":"8716_CR30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1053\/j.gastro.2021.05.047","volume":"161","author":"JD Lewis","year":"2021","unstructured":"Lewis JD, Sandler RS, Brotherton C et al. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn\u2019s disease. Gastroenterology 2021;161:837-852.e9.","journal-title":"Gastroenterology"},{"key":"8716_CR31","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1007\/s10620-023-07955-9","volume":"68","author":"R Kuang","year":"2023","unstructured":"Kuang R, Levinthal DJ, Ghaffari AA, del Aguila de Rivers CR, Tansel A, Binion DG. Nightshade vegetables: a dietary trigger for worsening inflammatory bowel disease and irritable bowel syndrome? Dig Dis Sci 2023;68:2853\u20132860. https:\/\/doi.org\/10.1007\/s10620-023-07955-9.","journal-title":"Dig Dis Sci"},{"key":"8716_CR32","first-page":"510","volume":"17","author":"K Robelin","year":"2021","unstructured":"Robelin K, Senada P, Ghoz H et al. Prevalence and clinician recognition of avoidant\/restrictive food intake disorder in patients with inflammatory bowel disease. Gastroenterol Hepatol 2021;17:510\u2013514.","journal-title":"Gastroenterol Hepatol"},{"key":"8716_CR33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cgh.2021.08.009","volume":"20","author":"E Yelencich","year":"2022","unstructured":"Yelencich E, Truong E, Widaman AM et al. Avoidant restrictive food intake disorder prevalent among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2022;20:1282-1289.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8716_CR34","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.3390\/jcm12216786","volume":"12","author":"A Bianco","year":"2023","unstructured":"Bianco A, Russo F, Franco I et al. Enhanced physical capacity and gastrointestinal symptom improvement in southern Italian IBS patients following three months of moderate aerobic exercise. J Clin Med 2023;12:6786.","journal-title":"J Clin Med"},{"key":"8716_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nmo.13461","volume":"31","author":"C Zhou","year":"2019","unstructured":"Zhou C, Zhao E, Li Y, Jia Y, Li F. Exercise therapy of patients with irritable bowel syndrome: a systematic review of randomized controlled trials. Neurogastroenterol Motil 2019;31:1\u201310.","journal-title":"Neurogastroenterol Motil"},{"key":"8716_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10620-023-08125-7","volume":"69","author":"A D\u2019Silva","year":"2024","unstructured":"D\u2019Silva A, Islam Z, Marshall DA et al. Experiences of irritable bowel syndrome patients in a virtual yoga program: qualitative findings from a clinical trial. Dig Dis Sci 2024;69:169\u2013179. https:\/\/doi.org\/10.1007\/s10620-023-08125-7.","journal-title":"Dig Dis Sci"},{"key":"8716_CR37","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s10620-019-05989-6","volume":"65","author":"A D\u2019Silva","year":"2020","unstructured":"D\u2019Silva A, MacQueen G, Nasser Y, Taylor LM, Vallance JK, Raman M. Yoga as a therapy for irritable bowel syndrome. Dig Dis Sci 2020;65:2503\u20132514. https:\/\/doi.org\/10.1007\/s10620-019-05989-6.","journal-title":"Dig Dis Sci"},{"key":"8716_CR38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.14309\/ajg.0000000000002052","volume":"118","author":"A D\u2019Silva","year":"2023","unstructured":"D\u2019Silva A, Marshall DA, Vallance JK et al. Meditation and yoga for irritable bowel syndrome: a randomized clinical trial. Am J Gastroenterol 2023;118:329\u2013337.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.explore.2023.06.011","volume":"19","author":"D Nunan","year":"2023","unstructured":"Nunan D, Cai T, Gardener A, et al. Physical activity for treatment of irritable bowel syndrome: summary of a Cochrane Review. Explore 2023;19:774\u2013775.","journal-title":"Explore"},{"key":"8716_CR40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jcag\/gwac028","volume":"6","author":"A D\u2019Silva","year":"2023","unstructured":"D\u2019Silva A, Marshall DA, Vallance JK et al. Gastroenterologist and patient attitudes toward yoga as a therapy for irritable bowel syndrome: an application of the theory of planned behaviour. J Can Assoc Gastroenterol 2023;6:17\u201325.","journal-title":"J Can Assoc Gastroenterol"},{"key":"8716_CR41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5217\/ir.2020.00049","volume":"20","author":"SP Davis","year":"2022","unstructured":"Davis SP, Crane PB, Bolin LP, Johnson LA. An integrative review of physical activity in adults with inflammatory bowel disease. Intest Res 2022;20:43\u201352.","journal-title":"Intest Res"},{"key":"8716_CR42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MCO.0000000000000829","volume":"25","author":"J Mareschal","year":"2022","unstructured":"Mareschal J, Douissard J, Genton L. Physical activity in inflammatory bowel disease: benefits, challenges and perspectives. Curr Opin Clin Nutr Metab Care 2022;25:159\u2013166.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"8716_CR43","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jcag\/gwad021","volume":"6","author":"B Oketola","year":"2023","unstructured":"Oketola B, Akinrolie O, Webber S et al. Physical activity for quiescent and mildly active inflammatory bowel disease: a systematic review and meta-analysis. J Can Assoc Gastroenterol 2023;6:162\u2013171.","journal-title":"J Can Assoc Gastroenterol"},{"key":"8716_CR44","first-page":"CD013589","volume":"7","author":"V Sinopoulou","year":"2021","unstructured":"Sinopoulou V, Gordon M, Dovey TM, Akobeng AK. Interventions for the management of abdominal pain in ulcerative colitis. Cochrane Database Syst Rev 2021;7:CD013589.","journal-title":"Cochrane Database Syst Rev"},{"key":"8716_CR45","first-page":"CD013531","volume":"11","author":"V Sinopoulou","year":"2021","unstructured":"Sinopoulou V, Gordon M, Akobeng AK et al. Interventions for the management of abdominal pain in Crohn\u2019s disease and inflammatory bowel disease. Cochrane Database Syst Rev 2021;11:CD013531.","journal-title":"Cochrane Database Syst Rev"},{"key":"8716_CR46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","volume":"114","author":"AC Ford","year":"2019","unstructured":"Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome. Am J Gastroenterol 2019;114:21\u201339.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR47","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2016.69","volume":"8","author":"S Ballou","year":"2017","unstructured":"Ballou S, Keefer L. Psychological interventions for irritable bowel syndrome and inflammatory bowel diseases. Clin Transl Gastroenterol 2017;8:e214.","journal-title":"Clin Transl Gastroenterol"},{"key":"8716_CR48","first-page":"1613","volume":"68","author":"HA Everitt","year":"2019","unstructured":"Everitt HA, Landau S, Reilly GO et al. Assessing telephone-delivered cognitive\u2013behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut 2019;68:1613\u20131623.","journal-title":"Gut"},{"key":"8716_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-020-01553-z","volume":"21","author":"J Chen","year":"2021","unstructured":"Chen J, Chen X, Sun Y et al. The physiological and psychological effects of cognitive behavior therapy on patients with inflammatory bowel disease before COVID-19: a systematic review. BMC Gastroenterol 2021;21:1\u201311.","journal-title":"BMC Gastroenterol"},{"key":"8716_CR50","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/j.gastro.2022.06.028","volume":"163","author":"JK Zia","year":"2022","unstructured":"Zia JK, Lenhart A, Yang P et al. Risk factors for abdominal pain-related disorders of gut\u2013brain interaction in adults and children: a systematic review. Gastroenterology 2022;163:995-1023.e3.","journal-title":"Gastroenterology"},{"key":"8716_CR51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jad.2023.03.033","volume":"331","author":"M Liu","year":"2023","unstructured":"Liu M, Ye Z, Wu Q et al. Healthy sleep, mental health, genetic susceptibility, and risk of irritable bowel syndrome. J Affect Disord 2023;331:25\u201332.","journal-title":"J Affect Disord"},{"key":"8716_CR52","first-page":"1","volume":"360","author":"JK Salwen-Deremer","year":"2020","unstructured":"Salwen-Deremer JK, Siegel CA, Smith MT. Cognitive behavioral therapy for insomnia: a promising treatment for insomnia, pain, and depression in patients with IBD. Crohn\u2019s Colitis 2020;360:1\u20138.","journal-title":"Crohn\u2019s Colitis"},{"key":"8716_CR53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10880-019-09621-7","volume":"27","author":"MG Hunt","year":"2020","unstructured":"Hunt MG, Loftus P, Accardo M, Keenan M, Cohen L, Osterman MT. Self-help cognitive behavioral therapy improves health-related quality of life for inflammatory bowel disease patients: a randomized controlled effectiveness trial. J Clin Psychol Med Settings 2020;27:467\u2013479.","journal-title":"J Clin Psychol Med Settings"},{"key":"8716_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40814-021-00829-9","volume":"7","author":"L Sweeney","year":"2021","unstructured":"Sweeney L, Moss-Morris R, Czuber-Dochan W, Norton C. Pain management in inflammatory bowel disease: feasibility of an online therapist-supported CBT-based self-management intervention. Pilot Feasibility Stud 2021;7:1\u201315.","journal-title":"Pilot Feasibility Stud"},{"key":"8716_CR55","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/jgh3.12817","volume":"6","author":"A Barnes","year":"2022","unstructured":"Barnes A, Mountifield R, Baker J, Spizzo P, Bampton P, Mukherjee S. Systematic review and meta-analysis of sleep quality in inactive inflammatory bowel disease. JGH Open 2022;6:738\u2013744.","journal-title":"JGH Open"},{"key":"8716_CR56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.gtc.2017.08.008","volume":"46","author":"MM Hood","year":"2017","unstructured":"Hood MM, Jedel S. Mindfulness-based interventions in inflammatory bowel disease. Gastroenterol Clin N Am 2017;46:859\u2013874.","journal-title":"Gastroenterol Clin N Am"},{"key":"8716_CR57","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.crohns.2014.01.018","volume":"8","author":"JW Berrill","year":"2014","unstructured":"Berrill JW, Sadlier M, Hood K, Green JT. Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohn\u2019s Colitis 2014;8:945\u2013955.","journal-title":"J Crohn\u2019s Colitis"},{"key":"8716_CR58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jpsychores.2018.11.010","volume":"116","author":"T Ewais","year":"2019","unstructured":"Ewais T, Begun J, Kenny M et al. A systematic review and meta-analysis of mindfulness based interventions and yoga in inflammatory bowel disease. J Psychosom Res 2019;116:44\u201353.","journal-title":"J Psychosom Res"},{"key":"8716_CR59","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/00029157.2015.1011465","volume":"57","author":"GR Elkins","year":"2015","unstructured":"Elkins GR, Barabasz AF, Council JR, Spiegel D. Advancing research and practice: the Revised APA Division 30 Definition of Hypnosis. Am J Clin Hypn 2015;57:378\u2013385.","journal-title":"Am J Clin Hypn"},{"key":"8716_CR60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00029157.2015.1040112","volume":"58","author":"E Szigethy","year":"2015","unstructured":"Szigethy E. Hypnotherapy for inflammatory bowel disease across the lifespan. Am J Clin Hypn 2015;58:81\u201399.","journal-title":"Am J Clin Hypn"},{"key":"8716_CR61","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/apt.13202","volume":"41","author":"SL Peters","year":"2015","unstructured":"Peters SL, Muir JG, Gibson PR. Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:1104\u20131115.","journal-title":"Aliment Pharmacol Ther"},{"key":"8716_CR62","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/ecco-jcc\/jjaa241","volume":"15","author":"DR Hoekman","year":"2021","unstructured":"Hoekman DR, Vlieger AM, Stokkers PC et al. Hypnotherapy for irritable bowel syndrome-type symptoms in patients with quiescent inflammatory bowel disease: a randomized, controlled trial. J Crohn\u2019s Colitis 2021;15:1106\u20131113.","journal-title":"J Crohn\u2019s Colitis"},{"key":"8716_CR63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2019.08.026","volume":"2020","author":"ZZRM Weerts","year":"2020","unstructured":"Weerts ZZRM, Masclee AAM, Witteman BJM et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology 2020;2020:123\u2013136.","journal-title":"Gastroenterology"},{"key":"8716_CR64","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.14309\/ajg.0000000000001395","volume":"116","author":"J Nee","year":"2021","unstructured":"Nee J, Ballou S, Kelley J et al. Peppermint oil treatment for irritable bowel syndrome: a randomized placebo-controlled trial. Am J Gastroenterol 2021;116:2279\u20132285.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR65","first-page":"1","volume":"13","author":"Y Shi","year":"2022","unstructured":"Shi Y, Tao Q, Qin D, Chen M, Yu S, Zheng H. Acupuncture vs. antispasmodics in the treatment of irritable bowel syndrome: an adjusted indirect treatment comparison meta-analysis. Front Physiol 2022;13:1\u201311.","journal-title":"Front Physiol"},{"key":"8716_CR66","doi-asserted-by":"crossref","first-page":"1251470","DOI":"10.3389\/fnins.2023.1251470","volume":"17","author":"Y Yang","year":"2023","unstructured":"Yang Y, Wang J, Zhang C et al. The efficacy and neural mechanism of acupuncture therapy in the treatment of visceral hypersensitivity in irritable bowel syndrome. Front Neurosci 2023;17:1251470.","journal-title":"Front Neurosci"},{"key":"8716_CR67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1142\/S0192415X21500154","volume":"49","author":"K Yaklai","year":"2021","unstructured":"Yaklai K, Pattanakuhar S, Chattipakorn N, Chattipakorn SC. The role of acupuncture on the gut\u2013brain\u2013microbiota axis in irritable bowel syndrome. Am J Chin Med 2021;49:285\u2013314.","journal-title":"Am J Chin Med"},{"key":"8716_CR68","first-page":"1","volume":"45","author":"C Bao","year":"2022","unstructured":"Bao C, Wu L, Wang D et al. Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn\u2019s disease: a randomized controlled trial. EClinicalMedicine 2022;45:1\u201314.","journal-title":"EClinicalMedicine"},{"key":"8716_CR69","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12906-020-03101-4","volume":"20","author":"X Wang","year":"2020","unstructured":"Wang X, Zhao N, Sun Y et al. Acupuncture for ulcerative colitis: a systematic review and meta-analysis of randomized clinical trials. BMC Complement Med Ther 2020;20:309.","journal-title":"BMC Complement Med Ther"},{"key":"8716_CR70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.gastro.2022.04.017","volume":"163","author":"A Lembo","year":"2022","unstructured":"Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology 2022;163:137\u2013151.","journal-title":"Gastroenterology"},{"key":"8716_CR71","first-page":"82","volume":"77","author":"MA Mart\u00ednez-V\u00e1zquez","year":"2012","unstructured":"Mart\u00ednez-V\u00e1zquez MA, V\u00e1zquez-Elizondo G, Gonz\u00e1lez-Gonz\u00e1lez JA, Guti\u00e9rrez-Udave R, Maldonado-Garza HJ, Bosques-Padilla FJ. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex 2012;77:82\u201390.","journal-title":"Rev Gastroenterol Mex"},{"key":"8716_CR72","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.14309\/ajg.0000000000001266","volume":"116","author":"DM Brenner","year":"2021","unstructured":"Brenner DM, Lacy BE. Antispasmodics for chronic abdominal pain: analysis of North American treatment options. Am J Gastroenterol 2021;116:1587\u20131600.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"L Zheng","year":"2021","unstructured":"Zheng L, Lu W, Xiao Q et al. Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial. Sci Rep 2021;11:1\u201313.","journal-title":"Sci Rep"},{"key":"8716_CR74","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3748\/wjg.15.1548","volume":"15","author":"R Rahimi","year":"2009","unstructured":"Rahimi R, Nikfar S, Rezale A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009;15:1548\u20131553.","journal-title":"World J Gastroenterol"},{"key":"8716_CR75","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2169\/internalmedicine.52.9147","volume":"52","author":"G Qun Chao","year":"2013","unstructured":"Qun Chao G, Zhang S. A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome. Intern Med 2013;52:419\u2013424.","journal-title":"Intern Med"},{"key":"8716_CR76","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41575-019-0259-y","volume":"17","author":"A Mikocka-Walus","year":"2020","unstructured":"Mikocka-Walus A, Ford AC, Drossman DA. Antidepressants in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:184\u2013192.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8716_CR77","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)01523-4","volume":"402","author":"AC Ford","year":"2023","unstructured":"Ford AC, Wright-hughes A, Alderson SL et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:1773\u20131785.","journal-title":"Lancet"},{"key":"8716_CR78","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MCG.0000000000000049","volume":"48","author":"HN Iskandar","year":"2014","unstructured":"Iskandar HN, Cassell B, Kanuri N et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol 2014;48:423\u2013429.","journal-title":"J Clin Gastroenterol"},{"key":"8716_CR79","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4103\/1735-1995.165969","volume":"20","author":"H Daghaghzadeh","year":"2015","unstructured":"Daghaghzadeh H, Naji F, Afshar H et al. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study. J Res Med Sci 2015;20:595\u2013601.","journal-title":"J Res Med Sci"},{"key":"8716_CR80","first-page":"CD012680","volume":"4","author":"A Mikocka-Walus","year":"2019","unstructured":"Mikocka-Walus A, Prady SL, Pollok J, et al. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst Rev 2019;4:CD012680.","journal-title":"Cochrane Database Syst Rev"},{"key":"8716_CR81","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.cgh.2011.08.008","volume":"9","author":"SD Dorn","year":"2011","unstructured":"Dorn SD, Meek PD, Shah ND. Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics. Clin Gastroenterol Hepatol 2011;9:1078-1085.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8716_CR82","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.cgh.2021.07.006","volume":"19","author":"L Keefer","year":"2021","unstructured":"Keefer L, Ko CW, Ford AC. AGA clinical practice update on management of chronic gastrointestinal pain in disorders of gut\u2013brain interaction: expert review. Clin Gastroenterol Hepatol 2021;19:2481-2488.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8716_CR83","first-page":"1","volume":"360","author":"X Lin","year":"2020","unstructured":"Lin X, Lofland J, Zhang L et al. Opioid use in patients with inflammatory bowel disease. Crohn\u2019s Colitis 2020;360:1\u20137.","journal-title":"Crohn\u2019s Colitis"},{"key":"8716_CR84","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/ibd\/izad156","volume":"30","author":"RS Dalal","year":"2023","unstructured":"Dalal RS, Lund K, Zegers FD, Friedman S, Allegretti JR, N\u00f8rg\u00e5rd BM. Use of tramadol vs traditional opioids and adverse outcomes in patients with inflammatory bowel disease: a Danish nationwide cohort study. Inflamm Bowel Dis 2023;30:1121\u20131129.","journal-title":"Inflamm Bowel Dis"},{"key":"8716_CR85","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/ibd\/izac021","volume":"28","author":"JL Sheehan","year":"2022","unstructured":"Sheehan JL, Jacob J, Berinstein EM et al. The relationship between opioid use and healthcare utilization in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2022;28:1904\u20131914.","journal-title":"Inflamm Bowel Dis"},{"key":"8716_CR86","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00384-021-03852-7","volume":"36","author":"P Kaimakliotis","year":"2021","unstructured":"Kaimakliotis P, Ramadugu A, Kang J et al. Targeted house staff intervention reduces opioid use without worsening patient-reported pain scores and improves outcomes among patients with IBD: the \u2018IBD pain ladder.\u2019 Int J Colorectal Dis 2021;36:1193\u20131200.","journal-title":"Int J Colorectal Dis"},{"key":"8716_CR87","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT Registry. Am J Gastroenterol 2012;107:1409\u20131422.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR88","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cgh.2017.10.022","volume":"16","author":"N Burr","year":"2018","unstructured":"Burr N, Smith C, West R, Hull M, Subramanian V. Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England. Clin Gastroenterol Hepatol 2018;16:534\u2013541.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8716_CR89","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/ajg.2014.230","volume":"109","author":"L Targownik","year":"2014","unstructured":"Targownik L, Nugent Z, Singh H, Bugden S, Bernstein C. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. Am J Gastroenterol 2014;109:1613\u20131620.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR90","first-page":"361","volume":"2","author":"AD Farmer","year":"2017","unstructured":"Farmer AD, Gallagher J, Bruckner-Holt C, Aziz Q. Narcotic bowel syndrome. Lancet. Gastroenterol Hepatol 2017;2:361\u2013368.","journal-title":"Gastroenterol Hepatol"},{"key":"8716_CR91","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s10620-019-05906-x","volume":"65","author":"SK Berry","year":"2020","unstructured":"Berry SK, Takakura W, Bresee C, Melmed GY. Pain in inflammatory bowel disease is not improved during hospitalization: the impact of opioids on pain and healthcare utilization. Dig Dis Sci 2020;65:1777\u20131783. https:\/\/doi.org\/10.1007\/s10620-019-05906-x.","journal-title":"Dig Dis Sci"},{"key":"8716_CR92","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s10620-019-05968-x","volume":"65","author":"MD Coates","year":"2020","unstructured":"Coates MD, Seth N, Clarke K, et al. Opioid analgesics do not improve abdominal pain or quality of life in Crohn\u2019s disease. Dig Dis Sci 2020;65:2379\u20132387. https:\/\/doi.org\/10.1007\/s10620-019-05968-x.","journal-title":"Dig Dis Sci"},{"key":"8716_CR93","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.14309\/ajg.0000000000000806","volume":"115","author":"RS Dalal","year":"2020","unstructured":"Dalal RS, Palchaudhuri S, Snider CK et al. A multimodal intervention using nonopioid analgesics is associated with reduced intravenous opioid exposure among hospitalized patients with inflammatory bowel diseases. Am J Gastroenterol 2020;115:1474\u20131485.","journal-title":"Am J Gastroenterol"},{"key":"8716_CR94","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/ibd\/izac156","volume":"29","author":"C Hsu","year":"2023","unstructured":"Hsu C, Ghannoum M, Cominelli F, Di Martino L. Mycobiome and inflammatory bowel disease: role in disease pathogenesis, current approaches and novel nutritional-based therapies. Inflamm Bowel Dis 2023;29:470\u2013479.","journal-title":"Inflamm Bowel Dis"},{"key":"8716_CR95","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3748\/wjg.v22.i3.1078","volume":"22","author":"O Nitzan","year":"2016","unstructured":"Nitzan O, Elias M, Peretz A, Saliba W. 2016 Inflammatory Bowel Disease: global view Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016;22:1078\u20131087.","journal-title":"World J Gastroenterol"},{"key":"8716_CR96","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1007\/s11605-023-05841-3","volume":"27","author":"SH Emile","year":"2023","unstructured":"Emile SH, Horesh N, Freund MR et al. A systematic review and meta-analysis of randomized clinical trials on the prevention and treatment of pouchitis after ileoanal pouch anastomosis. J Gastrointest Surg 2023;27:2650\u20132660.","journal-title":"J Gastrointest Surg"},{"key":"8716_CR97","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/jgh.15851","volume":"37","author":"K Fan","year":"2022","unstructured":"Fan K, Eslick GD, Nair PM et al. Human intestinal spirochetosis, irritable bowel syndrome, and colonic polyps: a systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:1222\u20131234.","journal-title":"J Gastroenterol Hepatol"},{"key":"8716_CR98","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","volume":"364","author":"M Pimentel","year":"2011","unstructured":"Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22\u201332.","journal-title":"N Engl J Med"},{"key":"8716_CR99","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.3748\/wjg.v17.i42.4643","volume":"17","author":"M Guslandi","year":"2011","unstructured":"Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol 2011;17:4643\u20134646.","journal-title":"World J Gastroenterol"},{"key":"8716_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000024059","volume":"100","author":"C Tocia","year":"2021","unstructured":"Tocia C, Dumitru IM, Alexandrescu L, Petcu LC, Dumitru E. Does rifaximin offer any promise in Crohn\u2019s disease in remission and concurrent irritable bowel syndrome-like symptoms? Medicine (Baltimore) 2021;100:1\u20137.","journal-title":"Medicine (Baltimore)"},{"key":"8716_CR101","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","volume":"159","author":"GL Su","year":"2020","unstructured":"Su GL, Ko CW, Bercik P et al. CLINICAL PRACTICE GUIDELINES AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology 2020;159:697\u2013705.","journal-title":"Gastroenterology"},{"key":"8716_CR102","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","volume":"48","author":"AC Ford","year":"2018","unstructured":"Ford AC, Quigley EMM, Harris LA, Lacy BE, Moayyedi P. Systematic review with meta-analysis\u202f: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018;48:1044\u20131060.","journal-title":"Aliment Pharmacol Ther"},{"key":"8716_CR103","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/j.gastro.2023.07.018","volume":"165","author":"VC Goodoory","year":"2023","unstructured":"Goodoory VC, Khasawneh M, Black CJ, Quigley EMM, Moayyedi P, Ford AC. Efficacy of probiotics in irritable bowel syndrome: systematic. Gastroenterology 2023;165:1206\u20131218.","journal-title":"Gastroenterology"},{"key":"8716_CR104","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.sjbs.2022.02.044","volume":"29","author":"S Selvamani","year":"2022","unstructured":"Selvamani S, Mehta V, Ali H et al. Saudi Journal of Biological Sciences efficacy of probiotics-based interventions as therapy for inflammatory bowel disease: a recent update. Saudi J Biol Sci 2022;29:3546\u20133567.","journal-title":"Saudi J Biol Sci"},{"key":"8716_CR105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.mcg.0000128929.37156.a7","volume":"38","author":"P Marteau","year":"2004","unstructured":"Marteau P, Seksik P. Tolerance of probiotics and prebiotics. J Clin Gastroenterol 2004;38:67\u201369.","journal-title":"J Clin Gastroenterol"},{"key":"8716_CR106","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.cgh.2023.07.031","volume":"21","author":"M Camilleri","year":"2023","unstructured":"Camilleri M, Zheng T. Cannabinoids and the gastrointestinal tract. Clin Gastroenterol Hepatol 2023;21:3217\u20133229.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8716_CR107","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000517425","volume":"4","author":"K Bogale","year":"2021","unstructured":"Bogale K, Raup-Konsavage W, Dalessio S, Vrana K, Coates MD. Cannabis and cannabis derivatives for abdominal pain management in inflammatory bowel disease. Med Cannabis Cannabinoids 2021;4:97\u2013106.","journal-title":"Med Cannabis Cannabinoids"},{"key":"8716_CR108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2019.102242","volume":"48","author":"S Pandey","year":"2020","unstructured":"Pandey S, Kashif S, Youssef M et al. Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy. Complement Ther Med 2020;48:102242.","journal-title":"Complement Ther Med"},{"key":"8716_CR109","volume":"12","author":"P Desai","year":"2020","unstructured":"Desai P, Mbachi C, Vohra I, et al. Association between cannabis use and healthcare utilization in patients with irritable bowel syndrome: a retrospective cohort study. Cureus 2020;12:e8008.","journal-title":"Cureus"},{"key":"8716_CR110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/10826084.2019.1664591","volume":"55","author":"RS Patel","year":"2020","unstructured":"Patel RS, Goyal H, Satodiya R, Tankersley WE. Relationship of cannabis use disorder and irritable bowel syndrome (IBS): an analysis of 6.8 million hospitalizations in the United States. Subst Use Misuse 2020;55:281\u2013290.","journal-title":"Subst Use Misuse"},{"key":"8716_CR111","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/00365521.2021.1998604","volume":"57","author":"J Wynne","year":"2022","unstructured":"Wynne J, Kozuch P. Medical marijuana for inflammatory bowel disease: the highs and lows. Scand J Gastroenterol 2022;57:197\u2013205.","journal-title":"Scand J Gastroenterol"},{"key":"8716_CR112","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000120","volume":"11","author":"M Kienzl","year":"2020","unstructured":"Kienzl M, Storr M, Schicho R. Cannabinoids and opioids in the treatment of inflammatory bowel diseases. Clin Transl Gastroenterol 2020;11:e00120.","journal-title":"Clin Transl Gastroenterol"},{"key":"8716_CR113","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/MCG.0000000000001393","volume":"55","author":"BH Doeve","year":"2021","unstructured":"Doeve BH, Van De Meeberg MM, Van Schaik FDM, Fidder HH. A systematic review with meta-analysis of the efficacy of cannabis and cannabinoids for inflammatory bowel disease: what can we learn from randomized and nonrandomized studies? J Clin Gastroenterol 2021;55:798\u2013809.","journal-title":"J Clin Gastroenterol"},{"key":"8716_CR114","volume":"15","author":"BN Nduma","year":"2023","unstructured":"Nduma BN, Mofor KA, Tatang J, Ekhator C, Ambe S, Fonkem E. The use of cannabinoids in the treatment of inflammatory bowel disease (IBD): a review of the literature. Cureus 2023;15:e36148.","journal-title":"Cureus"},{"key":"8716_CR115","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/ecco-jcc\/jjab069","volume":"15","author":"T Naftali","year":"2021","unstructured":"Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn\u2019s disease, a randomised controlled trial. J Crohn\u2019s Colitis 2021;15:1799\u20131806.","journal-title":"J Crohn\u2019s Colitis"},{"key":"8716_CR116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0246871","volume":"16","author":"T Naftali","year":"2021","unstructured":"Naftali T, Schleider LBL, Benjaminov FS, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: a randomized controlled trial. PLoS ONE 2021;16:1\u201313.","journal-title":"PLoS ONE"},{"key":"8716_CR117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0222577","volume":"14","author":"JH Ishida","year":"2019","unstructured":"Ishida JH, Wong PO, Cohen BE, Vali M, Steigerwald S, Keyhani S. Substitution of marijuana for opioids in a national survey of US adults. PLoS ONE 2019;14:1\u20138.","journal-title":"PLoS ONE"},{"key":"8716_CR118","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/ibd\/izaa104","volume":"27","author":"RS Dalal","year":"2021","unstructured":"Dalal RS, Palchaudhuri S, Snider CK, Lewis JD, Mehta SJ, Lichtenstein GR. Preadmission cannabis use is positively correlated with inpatient opioid dose exposure in hospitalized patients with inflammatory bowel diseases. Inflamm Bowel Dis 2021;27:500\u2013506.","journal-title":"Inflamm Bowel Dis"},{"key":"8716_CR119","first-page":"1","volume":"30","author":"D Glickman","year":"2023","unstructured":"Glickman D, Dalessio S, Raup-Konsavage WM, Vrana KE, Coates MD. The impact of cannabis use on clinical outcomes in inflammatory bowel disease: a population-based longitudinal cohort study. Inflamm Bowel Dis 2023;30:1\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"8716_CR120","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/MCG.0000000000001782","volume":"57","author":"R Greywoode","year":"2023","unstructured":"Greywoode R, Cunningham C, Hollins M, Aroniadis O. Medical cannabis use patterns and adverse effects in inflammatory bowel disease. J Clin Gastroenterol 2023;57:824\u2013829.","journal-title":"J Clin Gastroenterol"},{"key":"8716_CR121","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1176\/appi.ajp.2021.21060664","volume":"179","author":"MH Meier","year":"2022","unstructured":"Meier MH, Caspi A, R Knodt A et al. Long-term cannabis use and cognitive reserves and hippocampal volume in midlife. Am J Psychiatry 2022;179:362\u2013374.","journal-title":"Am J Psychiatry"},{"key":"8716_CR122","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1037\/pha0000326","volume":"28","author":"ME Lovell","year":"2020","unstructured":"Lovell ME, Akhurst J, Padgett C, Garry MI, Matthews A. Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: a meta-analysis. Exp Clin Psychopharmacol 2020;28:471\u2013494.","journal-title":"Exp Clin Psychopharmacol"},{"key":"8716_CR123","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.3390\/ijerph20065129","volume":"20","author":"A Velez-Santiago","year":"2023","unstructured":"Velez-Santiago A, Alvarez-Torres E, Martinez-Rodriguez R et al. A survey of cannabis use among patients with inflammatory bowel disease (IBD). Int J Environ Res Public Health 2023;20:5129.","journal-title":"Int J Environ Res Public Health"},{"key":"8716_CR124","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.3390\/healthcare11172442","volume":"11","author":"F Buffone","year":"2023","unstructured":"Buffone F, Tarantino AG, Belloni F et al. Effectiveness of osteopathic manipulative treatment in adults with irritable bowel syndrome: a systematic review and meta-analysis. Healthcare 2023;11:2442.","journal-title":"Healthcare"},{"key":"8716_CR125","first-page":"el3811","volume":"97","author":"GV Espi-Lopez","year":"2018","unstructured":"Espi-Lopez GV, Ingles M, Soliva-Cazaban I, Serra-Ano P. Effect of the soft-tissue techniques in the quality of life in patients with Crohn\u2019s disease. Medicine (Baltimore) 2018; 97: el3811.","journal-title":"Medicine (Baltimore)"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08716-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08716-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08716-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T18:15:36Z","timestamp":1739556936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08716-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":125,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["8716"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08716-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}